Prognostic significance of VEGF expression in osteosarcoma: a meta-analysis
- PMID: 23907576
- DOI: 10.1007/s13277-013-1019-1
Prognostic significance of VEGF expression in osteosarcoma: a meta-analysis
Abstract
Vascular endothelial growth factor (VEGF) is considered as a prime mediator of angiogenesis and has been implicated in carcinogenesis and metastasis. Various studies examined the relationship between VEGF overexpression with the clinical outcome in patients with osteosarcoma but yielded conflicting results. Electronic databases updated to April 2013 were searched to find relevant studies. A meta-analysis was conducted with eligible studies which quantitatively evaluated the relationship between VEGF overexpression and survival of patients with osteosarcoma. Survival data were aggregated and quantitatively analyzed. We performed a meta-analysis of eight studies that evaluated the correlation between VEGF overexpression and survival in patients with osteosarcoma. Combined hazard ratios suggested that VEGF overexpression had an unfavorable impact on overall survival (hazard ratio (HR) = 1.75, 95% confidence interval (CI): 1.21-2.28) in patients with osteosarcoma for overall populations, 2.37 (1.35-3.39) in Asian studies but not in non-Asian studies (HR = 1.51, 95% CI: 0.89-2.14). No significant heterogeneity was observed among all studies. VEGF overexpression indicates a poor prognosis for patients with osteosarcoma. However, the prognostic value of VEGF on survival in osteosarcoma patients still needs further large-scale prospective trials to be clarified.
Comment in
-
Comment on Xu XW et al.: Prognostic significance of VEGF expression in osteosarcoma: a meta-analysis.Tumour Biol. 2014 Jul;35(7):6193-4. doi: 10.1007/s13277-014-2024-8. Epub 2014 May 23. Tumour Biol. 2014. PMID: 24852425 No abstract available.
Similar articles
-
Prognostic significance of vascular endothelial growth factor immunohistochemical expression in gastric cancer: a meta-analysis.Mol Biol Rep. 2012 Oct;39(10):9473-84. doi: 10.1007/s11033-012-1812-8. Epub 2012 Jun 23. Mol Biol Rep. 2012. PMID: 22729879
-
The prognostic value of elevated vascular endothelial growth factor in patients with osteosarcoma: a meta-analysis and systemic review.J Cancer Res Clin Oncol. 2012 May;138(5):819-25. doi: 10.1007/s00432-012-1149-7. Epub 2012 Jan 25. J Cancer Res Clin Oncol. 2012. PMID: 22274866 Review.
-
Prognostic value of vascular endothelial growth factor A expression in gastric cancer: a meta-analysis.Tumour Biol. 2014 Mar;35(3):2787-93. doi: 10.1007/s13277-013-1371-1. Tumour Biol. 2014. PMID: 24234334
-
Prognostic significance of vascular endothelial growth factor expression in hepatocellular carcinoma tissue: a meta-analysis.Hepatobiliary Surg Nutr. 2013 Jun;2(3):148-55. doi: 10.3978/j.issn.2304-3881.2013.06.06. Hepatobiliary Surg Nutr. 2013. PMID: 24570933 Free PMC article.
-
The role of vascular endothelial growth factor as a prognostic and clinicopathological marker in osteosarcoma: a systematic review and meta-analysis.J Orthop Surg Res. 2021 Dec 28;16(1):738. doi: 10.1186/s13018-021-02888-3. J Orthop Surg Res. 2021. PMID: 34963495 Free PMC article. Review.
Cited by
-
Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma.Int J Mol Sci. 2016 Apr 6;17(4):506. doi: 10.3390/ijms17040506. Int J Mol Sci. 2016. PMID: 27058531 Free PMC article. Review.
-
Overexpression of vascular endothelial growth factor indicates poor outcomes of glioma: a systematic review and meta-analysis.Int J Clin Exp Med. 2015 Jun 15;8(6):8709-19. eCollection 2015. Int J Clin Exp Med. 2015. PMID: 26309522 Free PMC article.
-
Effects of vascular endothelial growth factor expression on pathological characteristics and prognosis of osteosarcoma.Clin Exp Med. 2016 Nov;16(4):577-584. doi: 10.1007/s10238-015-0382-1. Epub 2015 Aug 29. Clin Exp Med. 2016. PMID: 26319790
-
Vitronectin significantly influences prognosis in osteosarcoma.Int J Clin Exp Pathol. 2015 Sep 1;8(9):11364-71. eCollection 2015. Int J Clin Exp Pathol. 2015. PMID: 26617861 Free PMC article.
-
A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy.Int J Cancer. 2017 Oct 1;141(7):1469-1477. doi: 10.1002/ijc.30841. Epub 2017 Jul 3. Int J Cancer. 2017. PMID: 28631382 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous